First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension

Cécile Daccord¹, Igor Letovanec², Patrick Yerly³, Jonathan Bloch⁴, Adam Ogna¹, Laurent P Nicod^{1

5}, John-David Aubert^{6

5}

Affiliations

¹ Dept of Respiratory Medicine, Lausanne University Hospital, Lausanne, Switzerland.
² Dept of Pathology, Lausanne University Hospital, Lausanne, Switzerland.
³ Dept of Cardiology, Lausanne University Hospital, Lausanne, Switzerland.
⁴ Service and Central Laboratory of Hematology, Oncology Dept, Lausanne University Hospital, Lausanne, Switzerland.
⁵ Lung Transplantation Unit, Lausanne University Hospital, Lausanne, Switzerland.
⁶ Dept of Respiratory Medicine, Lausanne University Hospital, Lausanne, Switzerland john-david.aubert@chuv.ch.

PMID: 29348153
DOI: 10.1183/13993003.01694-2017

Free article

Comment

First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension

Cécile Daccord et al. Eur Respir J. 2018.

Free article

. 2018 Mar 1;51(3):1701694.

doi: 10.1183/13993003.01694-2017. Print 2018 Mar.

Authors

Cécile Daccord¹, Igor Letovanec², Patrick Yerly³, Jonathan Bloch⁴, Adam Ogna¹, Laurent P Nicod^{1

5}, John-David Aubert^{6

5}

Affiliations

¹ Dept of Respiratory Medicine, Lausanne University Hospital, Lausanne, Switzerland.
² Dept of Pathology, Lausanne University Hospital, Lausanne, Switzerland.
³ Dept of Cardiology, Lausanne University Hospital, Lausanne, Switzerland.
⁴ Service and Central Laboratory of Hematology, Oncology Dept, Lausanne University Hospital, Lausanne, Switzerland.
⁵ Lung Transplantation Unit, Lausanne University Hospital, Lausanne, Switzerland.
⁶ Dept of Respiratory Medicine, Lausanne University Hospital, Lausanne, Switzerland john-david.aubert@chuv.ch.

PMID: 29348153
DOI: 10.1183/13993003.01694-2017

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Comment on

Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.
Weatherald J, Chaumais MC, Savale L, Jaïs X, Seferian A, Canuet M, Bouvaist H, Magro P, Bergeron A, Guignabert C, Sitbon O, Simonneau G, Humbert M, Montani D. Weatherald J, et al. Eur Respir J. 2017 Jul 27;50(1):1700217. doi: 10.1183/13993003.00217-2017. Print 2017 Jul. Eur Respir J. 2017. PMID: 28751413

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- HighWire
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension

Affiliations

First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources